Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-28.57%
0%
-28.57%
6 Months
68.24%
0%
68.24%
1 Year
0%
0%
0.0%
2 Years
-88.21%
0%
-88.21%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Xtacy Therapeutics Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.30%
EBIT Growth (5y)
12.23%
EBIT to Interest (avg)
-0.61
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.41
EV to EBIT
-0.41
EV to EBITDA
-0.41
EV to Capital Employed
-0.41
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.10
-0.10
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.10
-0.10
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Sep'24
Sep'24
Sep'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.60
-0.50
-20.00%
Interest
0.00
0.00
Exceptional Items
0.10
0.00
Consolidate Net Profit
-0.50
-0.50
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023
Consolidated Net Profit
YoY Growth in year ended Sep 2024 is 0.00% vs 64.29% in Sep 2023
About Xtacy Therapeutics Corp. 
Xtacy Therapeutics Corp.
Capital Markets
Redfund Capital Corp is a Canada-based merchant bank. The Company is focused on medical cannabis and hemp in both Canada and the United States. It intends to provide debt and equity funding in the mid-to-late stages of a target company’s development or in technologies that are developed and validated by revenues. It also offers advisory services to companies.
Company Coordinates 
Company Details
1100 - 1111 Melville St , VANCOUVER BC : V6E 3V6
Registrar Details






